The FDA approved Rhythm's (RYTM) Imcivree for acquired hypothalamic obesity, making it the first and only approved therapy for the condition. The label covers patients aged 4 and older.

Eli Lilly (LLY) reported highly positive Phase 3 results for retatrutide, its first-in-class triple hormone receptor agonist, in type 2 diabetes. Patients on the highest dose lost an average of 36.6 lbs (16.8%) at 40 weeks with no plateau.

The Metabolic Monopoly: Between orforglipron (April 10 target action date), retatrutide (seven more Phase 3 readouts this year), and tirzepatide (Zepbound/Mounjaro), Lilly is building the most dominant metabolic franchise in pharma history.

Rhythm Commercial Launch: Imcivree is available to HO patients immediately through the Rhythm InTune patient support program. The 42-person sales force has been in the field since October. Watch Q2 earnings for the first HO revenue signal.

Lilly Retatrutide Obesity Data (Mid-2026): Three obesity-specific Phase 3 readouts are expected this year. The knee OA study (TRIUMPH-4) already showed up to 24% weight loss. The pure obesity data could exceed that. This will be the most-watched readout in metabolic medicine this year.

Orforglipron (April 10): Lilly's oral GLP-1 target action date remains the next major regulatory catalyst. An approval would give Lilly three distinct metabolic blockbusters spanning oral, injectable, and next-gen triple agonist formats.

Rocket Pharma (March 28): Kresladi PDUFA for LAD-I gene therapy. Approval would come with a highly lucrative Priority Review Voucher.

What Happened: The FDA approved an expanded indication for Rhythm Pharmaceuticals' (RYTM) Imcivree (setmelanotide) to treat patients with acquired hypothalamic obesity (HO), a rare condition characterized by accelerated weight gain caused by injury to the hypothalamus.

The Label: Approved for adults and pediatric patients aged 4 years and older. This is significantly broader than some analysts expected (many had modeled age 6+). The drug is available to U.S. patients immediately.

The Data: The pivotal Phase 3 TRANSCEND trial demonstrated a statistically significant 18.4% placebo-adjusted reduction in BMI. Responder rates were striking: 80% of patients achieved greater than 5% BMI reduction and 60% achieved greater than 10%.

Executive Impact: This is Imcivree's fourth approved indication and opens Rhythm's largest addressable market yet (~10,000 people in the U.S.). With the sales force already deployed and Imcivree generating $194M in 2025 revenue (+50% YoY), the revenue acceleration thesis is now fully in play.

What Happened: Eli Lilly announced positive topline results from TRANSCEND-T2D-1, the first Phase 3 trial evaluating retatrutide (a triple GIP/GLP-1/glucagon agonist) in type 2 diabetes.

The Numbers: Retatrutide met all primary and secondary endpoints. A1C reduced by 1.7% to 2.0% across doses (vs. 0.8% placebo). Weight loss at the 12 mg dose reached 36.6 lbs (16.8%) with no plateau observed at 40 weeks.

The Safety: Most common adverse events were GI-related, primarily during dose escalation. Dysesthesia (abnormal sensation) was reported in 2-5% of patients across doses, though it was generally mild and self-resolving.

Executive Impact: These numbers put the broader metabolic drug field on notice. BMO noted the weight loss is "meaningfully better than previous tirzepatide data." With seven more Phase 3 readouts expected in 2026—including pure obesity studies by mid-year—retatrutide is rapidly building the undeniable profile of a best-in-class metabolic therapy.

What Happened: The FDA published a draft guidance designed to help drug sponsors validate New Approach Methodologies (NAMs) that can bring safe, effective drugs to market using human-centric data rather than starting with traditional animal pharmacology and toxicology studies. The agency called this a "milestone move."

Executive Impact: This is a highly meaningful regulatory signal for companies building platforms around organoids, organ-on-chip technology, in silico modeling, and AI-driven toxicology prediction. While the practical impact on near-term timelines is limited, it provides a formal framework that preclinical-stage biotechs and CROs have been desperately waiting for. Watch for increased institutional interest in platform developers like Emulate and CN Bio.